Proceedings of the International scientific and practical conference ―New York Global Science Conference 2026‖ (May 18-20, 2026) / Publisher website: www.naukainfo.com. – New York, USA, 2026. - 322 p.

252 6. The obtained data confirm the feasibility of an individualised selection of antianginal therapy, taking into account the predominant effect of β-AB on HR and sympathetic tone, and of CCBs — on vascular resistance and blood pressure. Prospects for Further Research Further research will involve expanding the sample and including an assessment of the effect of therapy on electrocardiographic parameters for a comprehensive evaluation of treatment efficacy. REFERENCES: 1. Rinaldi, R., Kunadian, V., Crea, F., & Montone, R. A. (2025). Management of angina pectoris. Trends in Cardiovascular Medicine, 35(6), 341–350. DOI: https://doi.org/10.1016/j.tcm.2025.03.001 2. Kim, M. H., Yuan, S. L., Lee, K. M., Jin, X., Song, Z. Y., & Cho, Y. R. (2023). Clinical outcomes of calcium-channel blocker vs beta-blocker: from the Korean Acute Myocardial Infarction Registry. JACC Asia, 3(3), 446–454. DOI: https://doi.org/10.1016/j.jacasi.2023.02.006 3. Wang, M. S., Deng, J. W., Geng, W. Y., Zheng, R., Xu, H. L., & Dong, Y. (2025). Temporal trend and attributable risk factors of cardiovascular disease burden for adults 55 years and older in 204 countries/territories from 1990 to 2021. European Journal of Preventive Cardiology, 32(7), 539–552. DOI: https://doi.org/10.1093/eurjpc/zwae384